Cimicoxib

• CAT Number: R015785
• CAS Number: 265114-23-6
• Molecular Formula: C16H13ClFN3O3S
• Molecular Weight: 381.81
• Purity: ≥95%
• Synonyms: 4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide; 4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide; UR 8880
• Target: COX
• Storage: -20°C
• IUPAC Name: 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide
• InChI: InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)
• InChIKey: KYXDNECMRLFQMZ-UHFFFAOYSA-N
• SMILES: COC1=C(C=C(C=C1)C2=C(N=CN2C3=CC=C(C=C3)S(=O)(=O)N)Cl)F

Cimicoxib(CAT: R015785) is a selective cyclooxygenase-2 (COX-2) inhibitor primarily used in veterinary medicine to manage pain and inflammation associated with osteoarthritis in dogs. By specifically targeting COX-2, Cimicoxib helps reduce inflammation and pain without significantly affecting COX-1, which is responsible for maintaining normal gastrointestinal and renal function. This selective inhibition enhances its safety profile, minimizing side effects like gastrointestinal irritation commonly seen with non-selective NSAIDs. Cimicoxib is also studied for its potential in other inflammatory conditions, making it a valuable tool in veterinary pain management.